Latent variable indirect response joint modeling of a continuous and a categorical clinical endpoint
- 500 Downloads
Informative exposure–response modeling of clinical endpoints is important in drug development. There has been much recent progress in latent variable modeling of ordered categorical endpoints, including the application of indirect response (IDR) models and accounting for residual correlations between multiple categorical endpoints. This manuscript describes a framework of latent-variable-based IDR models that facilitate easy simultaneous modeling of a continuous and a categorical clinical endpoint. The model was applied to data from two phase III clinical trials of subcutaneously administered ustekinumab for the treatment of psoriatic arthritis, where Psoriasis Area and Severity Index scores and 20, 50, and 70 % improvement in the American College of Rheumatology response criteria were used as efficacy endpoints. Visual predictive check and external validation showed reasonable parameter estimation precision and model performance.
KeywordsDiscrete variable Multivariate analysis Population pharmacokinetic/pharmacodynamic modeling NONMEM Ustekinumab Psoriatic arthritis Well-controlled clinical trials
The authors thank the Medical Affairs Publication Group of Janssen Scientific Affairs, LLC for their excellent editorial support.
- 4.Lacroix BD, Lovern MR, Stockis A, Sargentini-Maier ML, Karlsson MO, Friberg LE (2009) A pharmacodynamic Markov mixed-effects model for determining the effect of exposure to certolizumab pegol on the ACR20 score in patients with rheumatoid arthritis. Clin Pharm Therap 86(4):387–395.Google Scholar
- 7.Hu C, Szapary PO, Yeilding N, Zhou H (2011) Informative dropout modeling of longitudinal ordered categorical data and model validation: application to exposure–response modeling of physician’s global assessment score for ustekinumab in patients with psoriasis. J Pharmacokinet Pharmacodyn 38(2):237–260PubMedCrossRefGoogle Scholar
- 10.Laffont CM, Fink M, Gruet P, King JN, Seewald W, Concordet D (2012) Application of a new method for multivariate analysis of longitudinal ordinal data testing robenacoxib in canine osteoarthritis. PAGE 21 Abstr:2548Google Scholar
- 11.Beal SL, Sheiner LB, Boeckmann A, Bauer RJ (2009) NONMEM user’s guides (1989–2009). Icon Development Solutions, Ellicott CityGoogle Scholar
- 13.Hu C, Zhang J, Zhou H (2011) Confirmatory analysis for phase III population pharmacokinetics. Pharm Stat 10(7):812–822Google Scholar
- 14.Zhu Y, Hu C, Lu M, Liao S, Marini JC, Yohrling J, Yeilding N, Davis HM, Zhou H (2009) Population pharmacokinetic modeling of ustekinumab, a human monoclonal antibody targeting IL-12/23p40, in patients with moderate to severe plaque psoriasis. J Clin Pharmacol 49(2):162–175PubMedCrossRefGoogle Scholar
- 16.Karlsson MO, Holford NHG (2008) A tutorial on visual predictive checks. PAGE 17:2008Google Scholar